TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23370149
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n=39) received 0.1 ml of purified Vero cell rabies vaccine (PVRV) intradermally on days 0 and 21.
Study: 23370149
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (n=16) received 0.5 ml of PVRV intramuscularly on days 0, 7, and 21.
Study: 19268499
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous administration)
Study: 19268499
Drug: Allopregnanolone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopregnanolone (intravenous administration)
Study: 16903602
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture therapy with motor therapy
Study: 16516010
Drug: Antimuscarinic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic therapy
Study: 10501823
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation of 200 mg p.o. per day
Study: 8568117
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (0.5 g twice daily)
Study: 7192117
Drug: Sulfamethoxydiazine administered
Normalized name: sulfamethoxypyridazine
DrugBank: Sulfamethoxypyridazine (DB13773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxydiazine administered with a test meal
Study: 7192117
Drug: Sulfamethoxydiazine administered
Normalized name: sulfamethoxypyridazine
DrugBank: Sulfamethoxypyridazine (DB13773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxydiazine administered with a high-lipid meal
Study: 7192117
Drug: Sulfamethoxydiazine administered
Normalized name: sulfamethoxypyridazine
DrugBank: Sulfamethoxypyridazine (DB13773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxydiazine administered with high-protein or high-carbohydrate meals
Study: 24257657
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (Group 3)
Study: 11348938
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol dry powder, 12 microg bid, in addition to ipratropium bromide, 40 microg qid for 3 weeks
Study: 2015175
Drug: Soluble ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble ibuprofen 400 mg
Study: 11215153
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg)
Study: 11301565
Drug: Nitrazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (5 mg)
Study: 26310877
Drug: High-dose nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nicotine dermal patches (n=90)
Study: 26310877
Drug: Low-dose nicotine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nicotine dermal patches (n=132)
Study: 26310877
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics (n=129)
Study: 26310877
Drug: Preparation stage
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation stage (n=97)
Study: 25367823
Drug: Composite intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite intervention consisting of education on recommended GWG according to IOM, application of personalised weight graph, formalised prescription of exercise and regular monitoring of GWG at every antenatal visit.
Study: 23551662
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy (LLLT) device
Study: 15827107
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (250 mg)
Study: 28640436
Drug: Single-dose cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cold compress
Study: 19815485
Drug: PC-SPES 960
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-SPES 960 mg t.i.d.
Study: 19815485
Drug: DES 3
Normalized name: Electrodes 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES 3 mg/day
Study: 18063208
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg IV
Study: 24061274
Drug: Trivalent seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent seasonal influenza vaccine (TIV)
Study: 26048455
Drug: Bicalutamide 50mg
Normalized name: BICALUTAMIDE 50MG TAB
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 50mg plus dutasteride 3.5mg once daily for 18 months
Study: 20025366
Drug: Group motivational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group motivational enhancement therapy (GMET)
Study: 3897471
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Adriamycin for six months
Study: 3277485
Drug: Lorazepam 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.06 mg/kg po 90 min preoperatively
Study: 3277485
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg/kg im plus scopolamine 0.006 mg/kg im 60 min preoperatively
Study: 17000820
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride gargle (15 mL, 0.15%)
Study: 17000820
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and benzydamine hydrochloride gargles
Study: 14681960
Drug: Eprosartan mesilat
Normalized name: Eprosartan mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan mesilat (600 mg daily)
Study: 14681960
Drug: Other hypotensive
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other hypotensive medicines (control group)
Study: 6428170
Drug: Propranolol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (180 mg/d)
Study: 31014469
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol intake (0.6 g/kg)
Study: 29462230
Drug: Oxymetazoline cream
Normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline cream 0.5%, 1.0%, or 1.5% applied topically once or twice daily for 28 days
Study: 29462230
Drug: Oxymetazoline cream
Normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline cream 1.5% applied twice daily
Study: 29462230
Drug: Oxymetazoline cream
Normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline cream (all concentrations)
Study: 27107460
Drug: Ceftazidime-avibactam (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime-avibactam (2000 mg ceftazidime plus 500 mg avibactam, administered via a 2-h intravenous infusion every 8 h for 5-21 days)
Study: 27107460
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (mostly carbapenems, 163 (97%) of 168 patients received a carbapenem, 161 (96%) as monotherapy)
Study: 12453954
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg
Study: 9972047
Drug: Antiparasitic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic treatment (after two weeks)
Study: 9972047
Drug: Trichinella spiralis
Normalized name: TRICHINELLA SPIRALIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichinella spiralis infection (before treatment)
Study: 25874510
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of octreotide infusion (50 μg/kg)
Study: 25874510
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of octreotide infusion (50 μg/kg)
Study: 21823284
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus acupoint injection with Methylcobalamin (group A)
Study: 21823284
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection with Methylcobalamin (group B)
Study: 19861283
Drug: Defibrase therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrase therapy
Study: 17559450
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) with local anaesthesia
Study: 17559450
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) without local anaesthesia
Study: 15768820
Drug: hylan B
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan B gel (n =47)
Study: 11454146
Drug: GLP-1 administered
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administered at the onset of a standard meal (550 kCal)
Study: 11454146
Drug: GLP-1 administered
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administered at 30 min after the start of the meal
Study: 11454146
Drug: GLP-1 administered
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administered at 60 min after the start of the meal
Study: 29939279
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg subcutaneously twice daily for 4 weeks)
Study: 19259349
Drug: Postoperative prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative prophylactic antibiotics (1.0 g Cefpiramide twice daily until the third day after surgery)
Study: 19259349
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no postoperative prophylactic antibiotics)
Study: 8860099
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg (LD-CAP)
Study: 8860099
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg (HD-CAP)
Study: 2179367
Drug: Controlled-release albuterol
Normalized name: albuterol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release albuterol
Study: 6814281
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline
Study: 94402
Drug: Probucol, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol, 500 mg twice daily for 20 weeks
Study: 25876706
Drug: Oral OKT3
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OKT3 5.0 mg/day (Group D)
Study: 25876706
Drug: Oral OKT3
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OKT3 0.2 mg/day (Group B)
Study: 12117397
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d)
Study: 10421920
Drug: NaCl post-operative
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl post-operative injection (3 ml)
Study: 18397971
Drug: Medication Event
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication Event Monitoring System (MEMS)
Study: 3543146
Drug: Intramuscular chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chloroquine
Study: 1346408
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether and chloroquine
Study: 6429092
Drug: Dose range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose range of 30 fractions between 1.6 and 2.1 Gy in 6 weeks
Study: 30804310
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge (twice daily for 1 month)
Study: 25407583
Drug: Telephone-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive behavioral therapy (T‐CBT)
Study: 20816836
Drug: 180 μg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg/wk peginterferon alfa‐2a for 48 weeks plus 1200 mg/day ribavirin (group A)
Study: 20816836
Drug: 1400/1600 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1400/1600 mg/day ribavirin (group B)
Study: 20816836
Drug: 360 μg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 μg/wk peginterferon alfa‐2a for 12 weeks then 180 μg/wk peginterferon alfa‐2a for 36 weeks plus 1200 mg/day ribavirin (group C)
Study: 20816836
Drug: 1400/1600 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1400/1600 mg/day ribavirin (group D)
Study: 11887035
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and combination treatment
Study: 11887035
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four treatments
Study: 9812111
Drug: Haloperidol 2-3
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2-3 mg/day (standard dose) in phase B
Study: 1571340
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (cyclosporine and azathioprine)
Study: 642793
Drug: OAP Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAP Chemotherapy
Study: 31158607
Drug: E0703 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0703 (30 mg oral administration)
Study: 9222732
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg three times daily
Study: 3687313
Drug: BAY m
Normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY m 1099 (3 X 50 mg/day) in non-diabetic controls
Study: 3687313
Drug: BAY m
Normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY m 1099 (2 X 25 mg/day) in type II diabetics
Study: 3687313
Drug: BAY o
Normalized name: Bay Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY o 1248 (15 mg single dose) in type II diabetics
Study: 25003151
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (10 ng · mL(‐1))
Study: 22370325
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg daily) alone
Study: 15696402
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 30 g/d
Study: 15696402
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 60 g/d
Study: 15696402
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 80 g/d
Study: 15696402
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB 10 g/d to 80 g/d
Study: 941864
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy in three different loci (unilateral loci used for weight loss, bilateral loci, unilateral loci not used for weight loss)
Study: 30099350
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (no treatment)
Study: 7893587
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 200 micrograms twice daily for 2 weeks
Study: 27232535
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate daily (37.5 mg iron)
Study: 25272653
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg)
Study: 15580061
Drug: 8-week low-cholesterol/low-saturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week low-cholesterol/low-saturated fat diet (30% total fat, 5% saturated fat, cholesterol <200 mg/daily)
Study: 17625917
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg)
Study: 2941770
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg)
Study: 14609009
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg)
Study: 9209604
Drug: Amrinone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1.0 mg/kg bolus followed by 10 micrograms/kg/min)
Study: 27798452
Drug: Modified double-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified double-injection group (MDI group)
Study: 27798452
Drug: Traditional double-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional double-injection group (DI group)
Study: 21872933
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (ET) - laser photocoagulation at high-risk prethreshold ROP
Study: 25968407
Drug: Pravastatin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (both doses)
Study: 19217695
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine cream
Study: 17760733
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg daily for 24 weeks
Study: 23885611
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium group (group B)
Study: 10618543
Drug: Hexavalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent meningococcal outer-membrane-vesicle vaccine (7.5 and 15 microg of individual PorA proteins)
Study: 10618543
Drug: Hexavalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent meningococcal outer-membrane-vesicle vaccine
Study: 10376615
Drug: Angiotensin‐converting‐enzyme (ACE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting‐enzyme (ACE) inhibitor
Study: 10376615
Drug: Calcium‐channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐channel blocker
Study: 8910814
Drug: Hyperglycaemia (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (20-30 mmol/l)
Study: 8910814
Drug: Euglycaemia (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (5-10 mmol/l)
Study: 25713599
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg
Study: 11079739
Drug: IGT/NFG (2-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGT/NFG (2-h glucose 7.8-11.0 mmol/l, fasting glucose < 6.1 mmol/l)
Study: 6375803
Drug: Bisacodyl (1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl (1.25, 2.5, and 5 mg)
Study: 28197834
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg
Study: 15759025
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination therapy (CCBs + ARBs)
Study: 15759025
Drug: High-dose CCBs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CCBs
Study: 10223241
Drug: NEO chemoendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO chemoendocrine therapy
Study: 10223241
Drug: ADJ chemoendocrine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADJ chemoendocrine therapy
Study: 25621943
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 0.5 mg every 4 weeks
Study: 25621943
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks
Study: 25621943
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) as-needed after 3 monthly doses
Study: 24101054
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg, day 1, 21-day cycle) plus erlotinib (150 mg per day)
Study: 22099189
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment (200 IU/kg•d, 3 times weekly for 2 to 4 weeks)
Study: 19085014
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment
Study: 15313090
Drug: Special training
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special training program using Solutions for Smoking as the main teaching tool
Study: 11776303
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (s.c. enoxaparin) and low dose aspirin
Study: 9763070
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg
Study: 29322401
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day mirabegron
Study: 24239431
Drug: Bupropion-SR 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion-SR 150 mg
Study: 22370318
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg/d
Study: 20480132
Drug: Aliskiren 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 600 mg